VitaSpring Biomedical Ltd. Overview
Get informed when a big investor buys or sells
+ Follow-13.83
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
VitaSpring Biomedical Ltd. (VSBC) currently reports a P/E ratio of -13.83. That is below the Healthcare sector average of 77.98. Use the charts on this page to explore VitaSpring Biomedical Ltd.'s P/E ratio history and peer comparisons.
VitaSpring Biomedical Ltd.'s P/E ratio of -13.83 is lower than the Healthcare sector average of 77.98. That is roughly 117.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates VitaSpring Biomedical Ltd.'s market price to a fundamental measure such as earnings, sales, or book value. At -13.83, VSBC can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -13.83, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 77.98. From there, open related valuation or income-statement pages for VitaSpring Biomedical Ltd., and consider following VSBC for alerts when major investors trade the stock.
VitaSpring Biomedical Ltd. is classified in the Healthcare sector. On P/E ratio, it currently shows -13.83 versus a sector average near 77.98. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing VSBC with unrelated industries.
